MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
12.67
-0.33 (-2.54%)
NASDAQ · Last Trade: Nov 22nd, 12:01 AM EST
Detailed Quote
Previous Close
13.00
Open
13.00
Bid
12.50
Ask
12.72
Day's Range
12.43 - 13.19
52 Week Range
5.950 - 62.75
Volume
2,311,315
Market Cap
-
PE Ratio (TTM)
-3.816
EPS (TTM)
-3.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,338,256
Chart
About MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
MoonLake Immunotherapeutics is a biopharmaceutical company focused on developing novel therapeutics for the treatment of autoimmune and inflammatory diseases. Leveraging its advanced proprietary platform, the company works on innovative approaches to enhance patient outcomes and address unmet medical needs in this therapeutic area. By integrating cutting-edge research and development strategies, MoonLake aims to bring new treatment options to market that can significantly improve the quality of life for individuals affected by chronic diseases. Their commitment to science and patient care drives their mission to transform the landscape of immunotherapy. Read More
NEW YORK - November 21, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) of a class action securities lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options
LOS ANGELES, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK - November 20, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) of a class action securities lawsuit.
NEW YORK - November 19, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) of a class action securities lawsuit.
NEW YORK - November 18, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) of a class action securities lawsuit.
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of aTyr Pharma, Inc. (NASDAQ:ATYR), Marex Group PLC (NASDAQ:MRX), Cepton, Inc. (NASDAQ:CPTN), and MoonLake Immunotherapeutics (NASDAQ:MLTX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK - November 17, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) of a class action securities lawsuit.
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
NEW YORK - November 14, 2025 ( NEWMEDIAWIRE ) - Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) and certain of its officers.
NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, inclusive.
LOS ANGELES, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK - November 12, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) of a class action securities lawsuit.
NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of aTyr Pharma, Inc. (NASDAQ:ATYR), Marex Group PLC (NASDAQ:MRX), Cepton, Inc. (NASDAQ:CPTN), and MoonLake Immunotherapeutics (NASDAQ:MLTX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
